Skin Cancer Model: TM01386

NSG™ mice engrafted with passage 7 tumors for model TM01386 were randomly assigned to one of these treatment groups:

• Control group (no treatment; N=5)
• Cisplatin (2 mg/kg; IV once per week for three times; N=5 )
• Vismodegib (100 mg/kg; PO once daily for three weeks; N=5)
• Dabrafenib + Trametinib combination (30 mg/kg; PO once daily for three weeks + 0.6 mg/kg; PO once daily for three weeks; N=5)

Mice were monitored for tumor volume at least twice per week throughout the study period.

• Treatment groups     • Individual subjects / spider plot     • RECIST scores     • Waterfall plot     • TGI plot         • Protocols